Saturday 17 October 2026
Export ADAG’s income statement to Excel — free account
Adagene Inc. Sponsored ADR
ADAG Healthcare Biotechnology
Adagene Inc. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $7.7 million, up 7,333.0% from fiscal 2024. Insiders bought in the last twelve months.
2.06
0.34
−14.17%
Follow ADAG
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 4 | 2 | 3 | 2 | 4 |
P/E ratio |
— | 0.00 | 0.00 | — | — | — | — | — |
Altman Z-Score |
— | — | — | 4.34 | (2.89) | (1.91) | (4.15) | (4.64) |
P/S ratio |
— | 0.00 | 0.00 | — | — | — | — | — |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | 2.46 | (3.17) | 4.75 | (3.92) | (2.91) | (9.06) | (10.30) |
P/Operating CF |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | — | 13.17 | 11.37 | (3.11) | (1.47) | (23.62) | 61.98 |
P/B ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | 0.00 | 0.00 | 0.00 | 0.91 | 0.67 | 0.60 | 1.04 |
EV/FCF |
— | 0.00 | 0.00 | 0.00 | 0.89 | 0.65 | 0.59 | 1.04 |
Quick Ratio |
— | 14.27 | 4.66 | 6.10 | 2.62 | 3.50 | 2.23 | 2.96 |
Current Ratio |
— | 14.47 | 4.90 | 6.24 | 2.71 | 3.61 | 2.30 | 3.07 |
Net Debt/EBITDA |
— | 5.39 | 1.68 | 2.39 | 1.53 | 4.06 | 2.04 | 3.46 |
Debt/Assets |
0.00% | 1.74% | 4.92% | 2.30% | 11.15% | 15.30% | 14.94% | 2.36% |
Debt/Equity |
— | (0.03) | (0.05) | 0.03 | 0.20 | 0.25 | 0.26 | 0.05 |
Asset Turnover |
— | 0.01 | 0.01 | 0.07 | 0.05 | 0.14 | 0.00 | 0.09 |
Operating CF/Net income |
— | 1.71 | 0.67 | 0.59 | 0.61 | 1.50 | 0.89 | 0.89 |
Capex/Depreciation |
— | (1.08) | (1.08) | (2.23) | (0.60) | (0.08) | (0.05) | (0.04) |
Interest Coverage |
— | (138.81) | (213.41) | (198.91) | (121.05) | (21.41) | (42.20) | (46.29) |
| — | 22.78% | 58.26% | (217.98%) | (66.74%) | (24.66%) | (55.21%) | (41.01%) | |
| — | (31.50%) | (44.85%) | (53.48%) | (46.78%) | (14.13%) | (32.61%) | (21.02%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | (16.91%) | (65.59%) | (45.86%) | (82.43%) | (22.60%) | (65.90%) | (33.28%) |
Average Days of Receivables |
— | 1,454.83 | 68.95 | 269.27 | 24.33 | 4.47 | 29.36 | 0.82 |
Research and Development Expense of Revenue |
— | 3,377.46% | 4,784.99% | 669.26% | 875.31% | 202.30% | 27,888.95% | 287.24% |
Selling, General and Administrative Expense of Revenue |
— | 716.23% | 1,471.61% | 141.91% | 127.78% | 47.89% | 7,047.77% | 92.24% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 2,110.31% | 1,445.21% | 183.58% | 113.21% | 40.15% | 4,757.36% | 48.78% |
Graham Net Nets |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | (8.90%) | (8.90%) | — | — | — | — | — |
Free Cash Flow Yield |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Revenue per Share |
— | 0.04 | 0.05 | 0.25 | 0.21 | 0.41 | 0.00 | 0.16 |
Operating CF per Share |
— | (2.35) | (2.24) | (1.08) | (1.12) | (0.65) | (0.66) | (0.33) |
Capex per Share |
— | (0.08) | (0.07) | (0.06) | (0.02) | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
— | (2.43) | (2.31) | (1.15) | (1.14) | (0.65) | (0.66) | (0.33) |
Cash per Share |
— | 8.28 | 5.89 | 4.36 | 3.32 | 2.51 | 1.89 | 1.58 |
Shareholders Equity per Share |
— | (4.69) | (7.00) | 3.91 | 1.92 | 1.61 | 1.12 | 0.75 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (4.69) | (7.00) | 3.91 | 1.92 | 1.61 | 1.12 | 0.75 |
Free Cash Flow |
— | (29.46) | (29.46) | (45.92) | (49.30) | (28.53) | (29.73) | (15.67) |
Working Capital |
— | 96.74 | 62.95 | 156.13 | 94.24 | 81.99 | 49.59 | 52.20 |
Capital Expenditures |
— | (0.93) | (0.93) | (2.51) | (0.69) | (0.08) | (0.03) | (0.02) |
Net Current Asset Value |
— | (58.98) | (94.56) | 153.00 | 80.01 | 68.27 | 49.03 | 34.46 |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | 1.93 | 1.32 | 0.25 | 0.07 | 0.00 | 0.32 | 0.00 |
| Other line items | ||||||||
Depreciation/Fixed assets |
— | 0.46 | 0.42 | 0.32 | 0.41 | 0.53 | 0.64 | 0.61 |
Cash ROIC |
— | (64.94%) | 291.96% | (13.70%) | (20.22%) | (14.40%) | (19.95%) | (14.03%) |
Accounts Receivable Turnover |
— | 0.47 | 0.69 | 2.66 | 2.29 | 43.05 | 0.90 | 599.29 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | 1.02 | 1.02 | 3.82 | 4.06 | 0.42 | 0.12 | 0.01 |
Average Payables |
— | 1.26 | 1.26 | 2.57 | 3.49 | 3.38 | 3.67 | 3.56 |
Average Assets |
— | 52.94 | 95.08 | 136.89 | 170.96 | 134.06 | 102.50 | 83.77 |
Average Common Equity |
— | (73.20) | (73.20) | 33.58 | 119.82 | 76.82 | 60.54 | 42.94 |
Columns are period end dates